Patent · US Active

Polypeptides antagonizing Wnt signaling in tumor cells

US12285493B2 · kind B2 · utility

0Cited by

4References

8Claims

0Family size

Assignee

Ablynx N.V. · BE

Inventors

Vittoria Zinzalla · Wien, AT
Klaus-Peter Kuenkele · Perchtoldsdorf, AT
Marie-Ange Buyse · Merelbeke, BE
Karen Cromie · Merelbeke, BE
Stephanie Staelens · Wevelgem, BE
Beatrijs Strubbe · Zwijnaarde, BE

Key dates

Filing date	May 10, 2021
Grant date	Apr 29, 2025
Priority date	—
Expiry date	Jun 10, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides LRP5-binding polypeptides, and more specifically LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.